This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Feb 1;42(3):408-10.

doi: 10.1086/499369. Epub 2005 Dec 27.

Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance

David Nolan, Elizabeth Phillips, Simon Mallal

PMID: 16392090
DOI: 10.1086/499369

Editorial

Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance

David Nolan et al. Clin Infect Dis. 2006.

. 2006 Feb 1;42(3):408-10.

doi: 10.1086/499369. Epub 2005 Dec 27.

Authors

David Nolan, Elizabeth Phillips, Simon Mallal

PMID: 16392090
DOI: 10.1086/499369

No abstract available

PubMed Disclaimer

Comment in

The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons.
Tong K, He ML, Lin CK, Guo L, Kung HF, Sung JJ, Lee SS. Tong K, et al. Clin Infect Dis. 2006 Aug 15;43(4):541-2; author reply 542-4. doi: 10.1086/505984. Clin Infect Dis. 2006. PMID: 16838248 No abstract available.

Comment on

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP; Adult AIDS Clinical Trials Group Study. Ribaudo HJ, et al. Clin Infect Dis. 2006 Feb 1;42(3):401-7. doi: 10.1086/499364. Epub 2005 Dec 27. Clin Infect Dis. 2006. PMID: 16392089

Similar articles

Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Mathiesen S, Justesen US, Von Lüttichau HR, Hansen AB. Mathiesen S, et al. Scand J Infect Dis. 2006;38(8):733-5. doi: 10.1080/00365540500504109. Scand J Infect Dis. 2006. PMID: 16857630
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. Tsuchiya K, et al. Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6. doi: 10.1016/j.bbrc.2004.05.116. Biochem Biophys Res Commun. 2004. PMID: 15194512
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Back DJ, Owen A, Khoo SH. Back DJ, et al. Clin Pharmacokinet. 2006;45(2):213-4; author reply 214-5. doi: 10.2165/00003088-200645020-00006. Clin Pharmacokinet. 2006. PMID: 16485918 No abstract available.
Clinical impact of patient population differences and genomic variation in efavirenz therapy.
King J, Aberg JA. King J, et al. AIDS. 2008 Sep 12;22(14):1709-17. doi: 10.1097/QAD.0b013e32830163ad. AIDS. 2008. PMID: 18753940 Review.
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V. Rodríguez-Nóvoa S, et al. Pharmacogenomics J. 2006 Jul-Aug;6(4):234-45. doi: 10.1038/sj.tpj.6500374. Epub 2006 Feb 7. Pharmacogenomics J. 2006. PMID: 16462814 Review.

See all similar articles

Cited by

Therapeutic efficacy of generic artemether-lumefantrine in the treatment of uncomplicated malaria in Ghana: assessing anti-malarial efficacy amidst pharmacogenetic variations.
Thomford NE, Kellermann T, Biney RP, Dixon C, Nyarko SB, Ateko RO, Ekor M, Kyei GB. Thomford NE, et al. Malar J. 2024 Apr 29;23(1):125. doi: 10.1186/s12936-024-04930-1. Malar J. 2024. PMID: 38685044 Free PMC article.
In vitro Assessment of the Effects of Silybin on CYP2B6-mediated Metabolism.
Zhang W, Zhang Y, Wen C, Jiang X, Wang L. Zhang W, et al. Planta Med. 2023 Oct;89(13):1195-1203. doi: 10.1055/a-2102-0648. Epub 2023 May 26. Planta Med. 2023. PMID: 37236224 Free PMC article.
Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study.
Altieri B, Sbiera S, Herterich S, De Francia S, Della Casa S, Calabrese A, Pontecorvi A, Quinkler M, Kienitz T, Mannelli M, Canu L, Angelousi A, Chortis V, Kroiss M, Terzolo M, Fassnacht M, Ronchi CL. Altieri B, et al. Cancers (Basel). 2020 Feb 4;12(2):359. doi: 10.3390/cancers12020359. Cancers (Basel). 2020. PMID: 32033200 Free PMC article.
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF, Neiner A, Kharasch ED. Wang PF, et al. Drug Metab Dispos. 2019 Oct;47(10):1195-1205. doi: 10.1124/dmd.119.086348. Epub 2019 Jul 19. Drug Metab Dispos. 2019. PMID: 31324697 Free PMC article. Review.
Insights into CYP2B6-mediated drug-drug interactions.
Hedrich WD, Hassan HE, Wang H. Hedrich WD, et al. Acta Pharm Sin B. 2016 Sep;6(5):413-425. doi: 10.1016/j.apsb.2016.07.016. Epub 2016 Aug 9. Acta Pharm Sin B. 2016. PMID: 27709010 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems